Published in Br J Clin Pharmacol on January 01, 1979
Improvement in angina pectoris with alpha adrenoceptor blockade. Br Heart J (1985) 1.44
Combined alpha- and beta-receptor inhibition in the treatment of hypertension. Drugs (1984) 0.90
Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris. Br J Clin Pharmacol (1987) 0.86
Beta-adrenoceptor blocking drugs: the relevance of intrinsic sympathomimetic activity. Br J Clin Pharmacol (1982) 0.80
Comparison of labetalol with other anti-hypertensive drugs. Br J Clin Pharmacol (1982) 0.78
Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol. Br J Clin Pharmacol (1982) 0.78
The influence of beta-adrenoceptor blockade on left ventricular function. Br J Clin Pharmacol (1982) 0.77
Pharmacology of combined alpha-beta-blockade. I. Drugs (1984) 0.76
The effect of intrinsic sympathomimetic activity of beta-adrenoceptor blockers on circadian heart rate. Br J Clin Pharmacol (1982) 0.75
Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium. Br J Clin Pharmacol (1979) 0.75
Atenolol versus pindolol: side-effects in hypertension. Eur J Clin Pharmacol (1985) 0.75
USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION. Br Med J (1964) 5.17
Comparison of antihypertensive activity of beta-blocking drugs during chronic treatment. Br Med J (1976) 2.23
Experience with pindolol, a betareceptor blocker, in the treatment of hypertension. Am J Med (1976) 1.46
The use of prindolol (Visken) in the treatment of hypertension. Med J Aust (1972) 1.38
How safe are beta-blocking drugs? Med J Aust (1977) 1.01
Effect of bronchodilator drugs on arterial blood gas tensions in bronchial asthma. Postgrad Med J (1971) 0.99
Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA (1996) 2.67
Use of antiasthmatic drugs in Australia. Med J Aust (1990) 2.47
Smoking as a risk factor for cerebral ischaemia. Lancet (1989) 2.26
Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. BMJ (1994) 2.25
Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med (2001) 2.19
Why older patients of lower clinical urgency choose to attend the emergency department. Intern Med J (2013) 2.19
The effects of bonus payments on emergency service performance in Victoria. Med J Aust (1999) 2.16
PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994-1998. Med J Aust (2001) 2.15
Hormone replacement therapy in postmenopausal women protects against smoking-induced changes in vascular structure and function. J Am Coll Cardiol (1999) 2.09
Trials of streptokinase in severe acute ischaemic stroke. Lancet (1995) 1.98
Risk factors for lacunar infarction syndromes. Neurology (1995) 1.97
Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg (1995) 1.75
Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. BMJ (1995) 1.70
Incidence of the major stroke subtypes: initial findings from the North East Melbourne stroke incidence study (NEMESIS). Stroke (2001) 1.69
Maxillofacial trauma in major trauma patients. Aust Dent J (2006) 1.68
Pharmacokinetics of the H2- receptor antagonist ranitidine in man. Br J Clin Pharmacol (1981) 1.67
Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology (1985) 1.54
Stroke incidence on the east coast of Australia: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke (2000) 1.48
Linking prescription and patient-identifying data: a pilot study. Med J Aust (1992) 1.48
High-pressure liquid chromatographic determination of ranitidine, a new H2-receptor antagonist, in plasma and urine. J Pharm Sci (1980) 1.46
The PACE pilot study: 12-month results and implications for future primary prevention trials in the elderly. (Prevention with low-dose Aspirin of Cardiovascular disease in the Elderly) J Am Geriatr Soc (1994) 1.45
Tampons: a novel patient-administered method for the assessment of genital human papillomavirus infection. J Infect Dis (1992) 1.44
Eosinophilia-myalgia syndrome: lessons for public health researchers. Med J Aust (1993) 1.44
Out-of-hospital cardiac arrest. Med J Aust (2000) 1.42
Asystolic cardiac arrest in Melbourne, Australia. Emerg Med (Fremantle) (2001) 1.41
Acute myocardial uptake of digoxin in humans: correlation with hemodynamic and electrocardiographic effects. J Am Coll Cardiol (1990) 1.41
Should smoking be an indication for lipid-lowering therapy? Med J Aust (1999) 1.40
Cardiac risk factor management. Experience of an outpatient hypertension clinic. Med J Aust (1991) 1.40
Pharmaceutical Benefits Scheme (PBS) Med J Aust (1994) 1.39
Hypertension and stroke. J Hypertens (1994) 1.38
Trends in prescribing of antihypertensive drugs in Australia, 1977-1987. Med J Aust (1990) 1.38
Australians with renal disease: a new national survey. Med J Aust (1999) 1.38
Influence of food on the bioavailability of a sustained-release verapamil preparation. J Pharm Sci (1990) 1.38
The use of prindolol (Visken) in the treatment of hypertension. Med J Aust (1972) 1.38
Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke (2001) 1.36
Beta-adrenergic receptor blocking drugs, hypertension and plasma renin. Br J Clin Pharmacol (1975) 1.34
Ischemic stroke risk and passive exposure to spouses' cigarette smoking. Melbourne Stroke Risk Factor Study (MERFS) Group. Am J Public Health (1999) 1.34
Informal care for stroke survivors: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke (2002) 1.31
The incidence of biopsy-proven glomerulonephritis in Australia. Nephrol Dial Transplant (2001) 1.30
Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. J Clin Epidemiol (2000) 1.30
The effectiveness of ranitidine in reducing gastric acid-secretion decreases with continued therapy. Br J Clin Pharmacol (1986) 1.28
Impact of a toxicology service on a metropolitan teaching hospital. Emerg Med (Fremantle) (2001) 1.27
Association of adult glioma with medical conditions, family and reproductive history. Int J Cancer (1997) 1.26
Hypertensive responses induced by phenylpropanolamine in anorectic and decongestant preparations. Lancet (1980) 1.24
Interrater reliability of the National Institutes of Health Stroke Scale: rating by neurologists and nurses in a community-based stroke incidence study. Cerebrovasc Dis (1999) 1.21
Plasma norepinephrine levels in essential hyoertension. N Engl J Med (1973) 1.20
Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis (2005) 1.17
An evaluation of laparoscopic versus open cholecystectomy. Med J Aust (1994) 1.16
Monitoring chemical exposure using breast milk: a methodological review. Am J Epidemiol (1992) 1.15
Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers. Br Med J (Clin Res Ed) (1985) 1.15
Double-blind controlled trial of ranitidine versus cimetidine in the treatment of duodenal ulceration. Aust N Z J Med (1982) 1.14
A randomized controlled clinical trial of pharmacokinetic theophylline dosing. Am Rev Respir Dis (1986) 1.13
Methyldopa and haemolytic anaemia. Med J Aust (1967) 1.13
High dose of antacid (Mylanta II) reduces bioavailability of ranitidine. Br Med J (Clin Res Ed) (1982) 1.13
Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther (1993) 1.12
Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. Br J Clin Pharmacol (1979) 1.10
Evaluation of indapamide in the treatment of hypertension. J Cardiovasc Pharmacol (1980) 1.10
Traumatic pneumobilia: case report. J Trauma (2001) 1.10
Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics. Int J Cardiol (1986) 1.10
Risk factors for stroke due to cerebral infarction in young adults. Stroke (1997) 1.08
Risk factors for cerebral hemorrhage in the era of well-controlled hypertension. Melbourne Risk Factor Study (MERFS) Group. Stroke (1996) 1.08
Measurement of carbamazepine and its epoxide metabolite by high-performance liquid chromatography, and a comparison of assay techniques for the analysis of carbamazepine. Clin Chem (1977) 1.07
Tumours of the brain and presence of antibodies to Toxoplasma gondii. Int J Epidemiol (1993) 1.07
Computerized neuropsychological tests in the early detection of dementia: prospective findings. J Int Neuropsychol Soc (1997) 1.06
Trends in Australian mortality of asthma, 1979-1985. Med J Aust (1989) 1.06
Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Melbourne Risk Factor Study Group. Hypertension (1998) 1.04
Risk factors for cardiovascular disease in chronic spinal cord injury patients. Paraplegia (1992) 1.04
Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension. Aust N Z J Med (1978) 1.04
Risk factors for development of flucloxacillin associated jaundice. BMJ (1993) 1.04
Blood-brain barrier disruption using mannitol: time course and electron microscopy studies. Am J Physiol (1989) 1.03
Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet (1978) 1.03
Drug doping in senior Australian rules football: a survey for frequency. Br J Sports Med (1997) 1.03
Dietary factors and the risk of glioma in adults: results of a case-control study in Melbourne, Australia. Int J Cancer (1994) 1.03
Ocular side effects with 5-fluorouracil. Aust N Z J Med (1979) 1.02
A comparison of chlorothiazide, chlorthalidone and cyclopenthiazide in the treatment of hypertension. Med J Aust (1973) 1.02
How safe are beta-blocking drugs? Med J Aust (1977) 1.01
Antismoking products. Med J Aust (1991) 1.01
Epidemiology of intracerebral hemorrhage. Epidemiol Rev (1995) 1.01
Effects of sodium intake on inherited hypertension in the rat. Lancet (1971) 1.00
Computerized delayed matching to sample and paired associate performance in the early detection of dementia. Appl Neuropsychol (1995) 1.00
Methods for detecting age-related maculopathy: a comparison between photographic and clinical assessment. Clin Experiment Ophthalmol (2000) 1.00
Nitroglycerin-induced tolerance affects multiple sites in the organic nitrate bioconversion cascade. J Pharmacol Exp Ther (1989) 0.99
Plasma dopamine -hydroxylase and noradrenaline amounts in essential hypertension. Clin Sci (1973) 0.99
Impact of a pharmacokinetics consultation service on clinical outcomes in an ambulatory-care epilepsy clinic. Am J Hosp Pharm (1988) 0.99
Results from the first 12 months of a fire first-responder program in Australia. Resuscitation (2001) 0.97
The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels. Clin Exp Pharmacol Physiol (1975) 0.96
The relationship between the vascular responses to the peptides ranatensin and angiotensin. Eur J Pharmacol (1971) 0.94
Inheritance of high blood-pressure in the spontaneously hypertnsive rat. Lancet (1969) 0.94
High-performance liquid chromatographic analysis of captopril in plasma. J Pharm Sci (1981) 0.94
Plasma renin levels and vascular complications in hypertension. Br Med J (1973) 0.94
The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function. Eur J Clin Pharmacol (1987) 0.93
A study of the alpha-1 adrenoceptor blocker prazosin in the prophylactic management of autonomic dysreflexia in high spinal cord injury patients. Clin Auton Res (1992) 0.93
Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines. Prostate (2008) 0.92
Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin. J Cardiovasc Pharmacol (1987) 0.92
Comparison of recruitment strategies for a large-scale clinical trial in the elderly. J Clin Epidemiol (1991) 0.92